IPO
Filter News
Found 17,237 articles
-
Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights
5/6/2021
Quarter highlights include FDA approval, launch and early market penetration of LUPKYNIS™ as the first approved oral therapy for lupus nephritis (LN)
-
BioLife Solutions to Report First Quarter 2021 Financial Results and Provide Business Update on May 13, 2021
5/6/2021
BioLife Solutions, Inc., a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, announced that the Company's first quarter 2021 financial results will be released after market close on Thursday, May 13, 2021, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon.
-
ProQR Announces First Quarter 2021 Operating and Financial Results
5/6/2021
Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retinitis pigmentosa, with plans to advance the program into two pivotal Phase 2/3 trials before year end
-
Xtant Medical Announces $20 Million Debt Financing with MidCap Financial
5/6/2021
Xtant Medical Holdings, Inc., a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced that the Company and its subsidiaries have entered into credit agreements with MidCap Financial Trust.
-
Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments
5/6/2021
Y-mAbs Therapeutics, Inc. a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, reported financial results for the first quarter of 2021.
-
Mirati Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Updates
5/6/2021
Initiated potentially registration-enabling trials evaluating our investigational KRASG12C inhibitor, adagrasib, in lung and colorectal cancers, as monotherapy and with other agents
-
MEI Pharma Reports Third Quarter Fiscal 2021 Results and Operational Highlights
5/6/2021
MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, reported results for the quarter ended March 31, 2021 and highlighted recent corporate progress.
-
Accelerate Diagnostics Reports First Quarter 2021 Financial Results
5/6/2021
Accelerate Diagnostics, Inc. announced financial results for the first quarter for the period ended March 31, 2021.
-
Calithera Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights
5/6/2021
Calithera Biosciences, Inc., a clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of cancer and other life-threatening diseases, announced its financial results for the first quarter ended March 31, 2021.
-
Accuray Incorporated Reports Inducement Awards Under NASDAQ Listing Rules - May 06, 2021
5/6/2021
Accuray Incorporated reported, as required by NASDAQ Listing Rules, equity inducement awards to Jean-Philippe Pignol, M.D., Ph.D., the company's new Chief Medical & Technology Officer.
-
Dynavax Announces First Quarter 2021 Financial Results
5/6/2021
Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, reported financial results for the first quarter of 2021.
-
Harpoon Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
5/6/2021
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.
-
Kura Oncology Reports First Quarter 2021 Financial Results
5/6/2021
Menin inhibitor KO-539 continues to demonstrate compelling clinical activity, favorable safety/tolerability and a wide therapeutic window
-
Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
5/6/2021
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced financial results for the first quarter ended March 31, 2021 and provided a corporate update.
-
Valneva Announces the Pricing of its Initial Public Offering on Nasdaq
5/6/2021
Saint-Herblain (France), May 6, 2021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced today the pricing of its initial public offering on the Nasdaq Global Select Market by way of a capital increase of 7,082,762 new ordinary shares, consisting of a public offering of 2,318,881 American Depositary Shares (“ ADSs ”), each representing two ordinary shares (th
-
Cardiff Oncology Announces First Quarter 2021 Results and Recent Highlights
5/6/2021
Cardiff Oncology, Inc., a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resistant prostate cancer, announced recent company highlights and financial results for the first quarter ended March 31, 2021.
-
Evofem Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Update
5/6/2021
Evofem Biosciences, Inc., reported financial results for the three-month period ended March 31, 2021.
-
Zogenix Provides Corporate Update and Reports First Quarter 2021 Financial Results
5/6/2021
Zogenix, a global biopharmaceutical company developing and commercializing rare disease therapies, announced financial results for the three months ended March 31, 2021, and provided a corporate update.
-
Philips Annual General Meeting of Shareholders approves all proposals
5/6/2021
Amsterdam, the Netherlands – Royal Philips announced that ’s Annual General Meeting of Shareholders has re-appointed Mr. Marnix van Ginneken as member of the Board of Management and appointed Mrs. Chua Sock Koong and Mrs. Indra Nooyi as members of the Supervisory Board.
-
Homology Medicines Reports First Quarter 2021 Financial Results and Recent Highlights
5/6/2021
Homology Medicines, Inc., a clinical-stage genetic medicines company, announced financial results for the first quarter ended March 31, 2021, and highlighted recent accomplishments.